Status:

UNKNOWN

Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer

Lead Sponsor:

Qianfoshan Hospital

Collaborating Sponsors:

Chinese Academy of Sciences

Conditions:

Type 2 Diabetes

Thyroid Cancer

Eligibility:

All Genders

18-75 years

Brief Summary

Persistent organic pollutants (POPs) are a class of organic pollutants in the environment characterized by persistent, bioaccumulation, long-range transport and biological toxicity. Due to its widespr...

Eligibility Criteria

Inclusion

  • Group of Type 2 diabetes patients:
  • age 18 \~ 75 years old;
  • type 2 diabetes patients diagnosed in the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) , HBA1C ≥7.0% and \<10.5% ;
  • patients signed informed consent.
  • Group of Thyroid Cancer patients:
  • age 18 \~ 75 years old;
  • thyroid cancer patients diagnosed in the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) ;
  • patients who signed the informed consent form.
  • Control Group:
  • age 18 \~ 75 years old;
  • healthy population recruited from the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) ;
  • living in the monitoring area for more than 6 months within 12 months;
  • normal thyroid function and no history of thyroid cancer were needed in the control group;
  • Fasting Blood Glucose level of 0.7 mmol/l was needed in the Control Group of Type 2 diabetes Mellitus Without History of diabetes;
  • patients with informed consent.

Exclusion

  • Group of Type 2 diabetes:
  • (1) pregnant, lactating women, patients with acute cardiac cerebrovascular disease; (2) patients with severe liver and Renal Impairment (related laboratory tests more than 2 times the normal) ; (3) patients with Type 1 diabetes; (4) participants in other clinical trials within 3 months; (5) patients with malignant tumors. (6) has the disease and so on serious anemia, is not suitable to carry on the patient which the blood draws the test.
  • Group of Thyroid Cancer:
  • patients with serious heart, liver and Kidney Diseases (related laboratory tests more than 2 times normal) ;
  • patients with other malignant tumors.
  • Control Group:
  • patients with serious heart, liver or kidney disease;
  • patients with iodine or Thyroid hormone;
  • patients with confirmed malignant tumor;
  • pregnant women or those who have recently taken contraception or estrogen.

Key Trial Info

Start Date :

December 20 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 30 2025

Estimated Enrollment :

900 Patients enrolled

Trial Details

Trial ID

NCT05218395

Start Date

December 20 2021

End Date

December 30 2025

Last Update

February 24 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xiaoling Guan

Jinan, Shandong, China